WEBULL

Assessing Sionna Therapeutics (SION) Valuation After A Sharp Share Price Move And Elevated Price To Book Ratio

Simply Wall St · 2d ago

Why Sionna Therapeutics (SION) is on investors’ radar today

Sionna Therapeutics (SION) has attracted fresh attention after a recent 16.1% one day move, as investors reassess this clinical stage cystic fibrosis developer.

See our latest analysis for Sionna Therapeutics.

That 16.1% one day share price return comes on top of a 46.9% 90 day share price return and a 10.2% year to date gain, suggesting momentum has been building rather than fading, with the stock now at $43.21.

If you are looking beyond a single CF-focused name, this could be a useful moment to scan other healthcare stocks that might fit a similar higher risk, higher reward profile.

After such a sharp upswing and with the share price sitting close to a US$46.75 analyst target, you have to ask yourself: is Sionna still mispriced, or is the market already baking in the next phase of growth?

Price-to-book of 6x: Is it justified?

On a P/B of 6x, Sionna is priced well above both its US biotech peers and its closest comparable group, even after the recent share price jump.

P/B compares a company’s market value to its net assets on the balance sheet, and it is often used for pre revenue or loss making biopharma names where earnings based metrics are less useful. For a business with essentially no reported revenue and a net loss of US$70.676m, a high P/B implies investors are placing a significant premium on the pipeline and future optionality rather than current financials.

Relative to the broader US biotech industry average P/B of 2.7x, Sionna trades at more than double that level. It is also above the peer group average of 5.3x, which suggests the current price reflects more optimism about its cystic fibrosis portfolio than the typical company in its space, at least on this balance sheet based yardstick.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 6x (OVERVALUED)

However, you still face clear risks here, including binary clinical outcomes across Sionna’s CF pipeline and the company’s US$70.676m net loss with no reported revenue yet.

Find out about the key risks to this Sionna Therapeutics narrative.

Build Your Own Sionna Therapeutics Narrative

If you see the numbers differently, or simply prefer to test your own assumptions against the data, you can build a personal thesis in minutes by starting with Do it your way.

A great starting point for your Sionna Therapeutics research is our analysis highlighting 4 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If you are ready to broaden your watchlist beyond a single name, this is a smart point to scan fresh ideas that match your risk and return preferences.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.